Central Texas Neurology Consultants

Round Rock, Texas 78681

3 studies enrolling now · 39 studies all time

What they study most

Alzheimer Disease, Alzheimer's Disease, Amyloid, Atypical Parkinsonism, Cervical Dystonia, Cognitive Dysfunction, Early Parkinson Disease (Early PD), Essential Tremor, Idiopathic Parkinson Disease, Lewy Body Disease, Multiple Sclerosis, Multiple Sclerosis (MS)

Studies at this site

• A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease — Recruiting now
• A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease — Recruiting now
• Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial — Running, not enrolling
• A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis — Running, not enrolling
• Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA) — Running, not enrolling
• A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease — Running, not enrolling
• A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80 — Completed
• A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1) — Completed
• AMX0035 and Progressive Supranuclear Palsy — Completed
• A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease — Running, not enrolling
• To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications — Running, not enrolling
• Early Parkinson's Disease Monotherapy With CVN424 — Completed
• A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease — Running, not enrolling
• A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease — Completed
• A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2) — Completed
• A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP) — Running, not enrolling
• A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) — Running, not enrolling
• A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD — Completed
• A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease — Stopped early
• A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD — Completed
• A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD) — Completed
• Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations — Completed
• A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration — Completed
• Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis — Stopped early
• A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis — Completed
• A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis — Completed
• Prospective Study for Symptomatic Relief of ET With Cala Therapy — Completed
• Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension — Completed
• Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) — Completed
• Single Treatment of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-1) — Completed
• Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS) — Completed
• Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) — Stopped early
• A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes — Completed
• A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) — Completed
• A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis — Completed
• Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis — NO_LONGER_AVAILABLE
• An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab — Completed